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Abstract
Background: Thymoma and thymic carcinoma are the most frequent subtypes of thymic epithelial tumors (TETs).
A relevant advance in TET management could derive from a deeper molecular characterization of these neoplasms. We
previously identified a set of microRNA (miRNAs) differentially expressed in TETs and normal thymic tissues and among
the most significantly deregulated we described the down-regulation of miR-145-5p in TET. Here we describe the
mRNAs diversely regulated in TETs and analyze the correlation between these and the miRNAs previously identified,
focusing in particular on miR-145-5p. Then, we examine the functional role of miR-145-5p in TETs and its
epigenetic transcriptional regulation.
Methods: mRNAs expression profiling of a cohort of fresh frozen TETs and normal tissues was performed
by microarray analysis. MiR-145-5p role in TETs was evaluated in vitro, modulating its expression in a Thymic Carcinoma
(TC1889) cell line. Epigenetic transcriptional regulation of miR-145-5p was examined by treating the TC1889 cell line
with the HDAC inhibitor Valproic Acid (VPA).
Results: Starting from the identification of a 69-gene signature of miR-145-5p putative target mRNAs, whose expression
was inversely correlated to that of miR-145-5p, we followed the expression of some of them in vitro upon overexpression
of miR-145-5p; we observed that this resulted in the down-regulation of the target genes, impacting on TETs cancerous
phenotype. We also found that VPA treatment of TC1889 cells led to miR-145-5p up-regulation and concomitant
down-regulation of miR-145-5p target genes and exhibited antitumor effects, as indicated by the induction of cell
cycle arrest and by the reduction of cell viability, colony forming ability and migration capability. The importance
of miR-145-5p up-regulation mediated by VPA is evidenced by the fact that hampering miR-145-5p activity by a
LNA inhibitor reduced the impact of VPA treatment on cell viability and colony forming ability of TET cells. Finally,
we observed that VPA was also able to enhance the response of TET cells to cisplatin and erlotinib.
Conclusions: Altogether our results suggest that the epigenetic regulation of miR-145-5p expression, as well as
the modulation of its functional targets, could be relevant players in tumor progression and treatment response
in TETs.
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Background
Thymic Epithelial Tumors (TETs) are rare tumors arising
from the thymic epithelium and they show a propensity to
recur and to metastasize that is difficult to predict [1].
Thymoma and thymic carcinoma (TC) are the most fre-
quent TETs types [2]. Although TETs classification has
been largely debated, now the World Health Organization
(WHO) histologic classification is widely accepted and
diffuse. WHO TETs subtypes are based on epithelial cell
morphology and lymphocytic infiltration [3–5]. While
type A, type AB and type B1 thymomas have a favorable
prognosis, type B2 and especially type B3 thymomas and
thymic carcinomas show an unfavorable outcome, in par-
ticular when diagnosed in an advanced tumor stage [6].
The 5-year recurrence rate reported by histotype was 4%
for type A, 2%for type AB, 8% for type B1, 13% for type
B2 and 14% for type B3, survival data being influenced by
the fact that type A thymoma occur in older patients.
Staging at diagnosis has been always considered the
major prognostic factor [7, 8], whereas histotype classifica-
tion has a limited prognostic relevance. Early diagnosis
and complete surgical excision are the main factors con-
tributing to a definitive treatment of TET. The unpredict-
able oncological properties of TETs, the preservation of
the thymopoietic activity at variable degrees, and the fre-
quent association with autoimmune diseases render TETs
unique and difficult to manage [9]. Treatment strategies
for newly diagnosed and recurrent TETs have evolved
over time [10] and novel therapeutic strategies are
emerging [11–14], even though the rarity of these tumors
hindered the feasibility of large clinical trial slowing their
development. Importantly, the oncogenic potential of
these rare neoplasms is still largely undefined and a deeper
molecular characterization could result in a relevant ad-
vance in their management greatly improving diagnosis,
prognosis and treatment choice [15, 16]. In this direction,
different studies investigated the epidermal growth factor
receptor (EGFR) as a potential therapeutic target in TETs.
Although EGFR mutations are rare in TETs, the receptor
has been shown frequently overexpressed in thymomas
and thymic carcinomas [17, 18]. However, the effective-
ness of EGFR-targeting therapies in TETs has not been
exhaustively clarified [12, 19–22]. Although single-case
reports suggest that EGFR-tyrosine kinase inhibitors
(Erlotinib or Gefitinib) or anti-EGFR mAb (Cetuximab)
may be effective in some patients, two clinical phase II
studies (44 patients in total) using Erlotinib and Gefitinib
reported no complete remissions and only two partial
responses [12, 15, 23]. These considerations suggest that
studies addressing novel therapeutic strategies and the
molecular basis of TETs are greatly needed. In this direc-
tion a recent work evidenced that Valproic Acid (VPA), a
histone deacetilase (HDAC) inhibitor, might markedly
increase the sensitivity of tyrosine kinase inhibitor (TKI)-
resistant lung adenocarcinoma cells to Erlotinib [24]. Based
on this evidence and on a recent phase I/II clinical trial
highlighting that the combination treatment of Belinostat,
an HDAC inhibitor, with chemotherapy agents was active
and feasible in TETs [25], we focalized our attention to
these epigenetic inhibitors as proof of concept to perform
combination treatments in TET cells and to study the im-
pact of the epigenetic regulation on TET phenotype.
Deregulation of epigenetic programs, as chromatin
“histone code” at specific gene sites, and the expression of
non-coding RNAs including microRNAs (miRNAs), co-
operate with genetic alterations in the establishment and
progression of tumors [26–28]. Interestingly, recent
evidences suggest that miRNAs and epigenetic path-
ways appear to form a complex regulatory circuit that
modulates the expression of an increasing number of
genes in the genome. In particular, miRNAs can repress
key enzymes that drive epigenetic remodeling [29]. More-
over, miRNAs can recruit Argonaute proteins and chroma-
tin modifier enzymes by specific binding to complementary
sites in gene promoters or by the interaction with target
sites in nascent coding/non-coding transcript [30]. Al-
though, epigenetics represents a novel field of research in
TET biology, also these tumors are emerging as epigeneti-
cally driven cancer [31, 32]. Recently, specific genetic and
epigenetic aberrations associated with different TET histo-
types have been identified, providing insight into the genes
involved in the pathogenesis of these tumors [33–42]. In
several tumors miRNAs expression profiling is emerging as
a significant tool for diagnosis, prognosis and treatment of
cancer and recently, deregulation of miRNAs expression
has been also established in TET patients [43, 44]. In
particular, our group contributed to the identification
of a signature of miRNAs deregulated in tumor versus
normal tissues, some of which were also detected as
circulating miRNAs in plasma [43, 45]. Interestingly,
expression levels of specific onco-miRNAs, that we
found up-regulated in the blood plasma collected from
TET patients at surgery, resulted significantly reduced
in follow-up samples [45]. Among the common miRNAs
deregulated in all TET histotype groups in comparison
with normal tissues, we observed the down-regulation of
miR-145-5p in TETs, in line with what previously reported
for other tumors [43, 46]. Several reports have revealed
that the down-regulation of miR-145-5p expression is
associated with neoplastic cell growth and proliferation as
well as with cancer cell migration, invasion and metastasis,
supporting miR-145-5p tumor suppressor activity in
different tumor types [46–50]. The tumor suppressive
functions of miR-145-5p were also reported in lung
cancer and in malignant pleural mesothelioma (MPM),
where the contribution of epigenetic transcriptional
regulation to the abnormally low levels of miR-145-5p
expression was recently described [51, 52]. Deciphering
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the molecular networks governed by miR-145-5p in
TETs may be relevant for a deep characterization of
these tumors and could lead to the design of new thera-
peutic strategies.
In this study we set out to address this question. We
analyzed the mRNA expression profile in a fresh frozen
cohort of tissues from TETs and normal counterparts,
and selected the putative miR-145-5p targets among the
mRNA differentially regulated. Thus we identified a 69-
gene signature of miR-145-5p putative target mRNAs
differently expressed between tumor and normal tissues
whose expression was inversely correlated to that of miR-
145-5p. We validated that Golm-1 and CDH-2, functionally
involved in the control of cell motility [48, 50], are directly
targeted by miR-145-5p also in TETcells. Genes controlling
cell motility are indeed of particular interest in TET, as
metastasis is a major issue in patients with advanced
disease. Then we investigated the function of miR-145-5p
in a TETcell line observing that miR-145-5p plays a tumor
suppressor role also in this biological system as described
in literature for others. Furthermore, we assessed that
miR-145-5p expression is epigenetically regulated in this
cell line. Indeed we evidenced that treatment of TET cells
with epigenetic drugs resulted in the induction of miR-
145-5p expression, with consequent down-regulation of
its target genes. This resulted in antitumor effects in terms
of cell cycle arrest and reduction of cell viability, colony
forming ability and migration capability.
Methods
Sample collection
Two independent cohorts of fresh frozen specimens
were utilized: four thymomas of different histotypes and
two thymi derived from the Pathology Department at
the Regina Elena National Cancer Institute; two thymomas
and one thymus derived from the “Policlinico Umberto I”
Hospital, Rome, Italy. The thymomas frozen samples in-
cluded: one type A, two type AB, two type B2, one type B3.
The normal thymi (normal thymic counterparts) included
peritumoral thymi of the same frozen series. All the frozen
specimens derived from extensive, prospective sampling of
surgical specimens. Frozen primary tumor samples and
matched normal thymi were checked for diagnosis on
frozen section and for consistency with the final patho-
logical diagnosis. Among the nineteen FFPE specimens
used for IHC analysis, fifteen TET derived from the
Pathology Department of Regina Elena National Cancer
Institute, four TET derived from the “Policlinico Umberto
I” Hospital, Rome, Italy [43]. There were five thymic car-
cinoma and fourteen thymomas of different histotypes
(one Type A, five Type AB, three Type B1, three Type B2,
two Type B3). Among the ten normal FFPE counterparts,
eight peritumoral thymi derived from the Regina Elena
National Cancer Institute, two from the “Policlinico
Umberto I” Hospital, Rome, Italy. Normal peritumoral
thymic tissues were selected from cases with a well-
represented epithelial cell compartment similar to hy-
perplastic thymic tissue, or from involuted thymus with
predominance of epithelial cells. Staining of normal
peritumoral thymic tissues for Cytokeratin 19 (CK19)
was used to evaluate the frequency of epithelial cells
both in hyperplastic thymus and in involuted thymus
[43]. Only primary tumors were included in the study.
The patients were not treated with any radio or radio-
chemotherapy before surgery. Independent Ethical Com-
mittees from collaborating Institutions have approved this
study.
RNA extraction, labeling and microarray hybridization
Fresh frozen samples were homogenized by gentleMACS
dissociator (Miltenyi Biotec, Bologna, Italy) in 700 μl of
Qiazol (Qiagen, Chatsworth, CA) and RNA was extracted
using the miRNAeasy® kit (Qiagen, Chatsworth, CA)
following the manufacturer’s instructions. The concen-
tration purity and quality of total RNA were assessed
using a Nanodrop TM 1000 spectrophotometer (Nanodrop
Technologies, Wilmington, DE, USA) and the Agilent 2100
Bioanalyzer (Agilent, Santa Clara, California, USA). Total
RNA for each specimen was labeled and used for
microarray analysis of mRNAs expression on Affymetrix
platform. Specifically, for mRNAs expression, 100 ng of
total RNA from fresh frozen tissues was hybridized on
“Affymetrix® Human Gene 2.0 ST Arrays 2.0” (Affymetrix,
Santa Clara, California). Scanning and image analysis were
performed using the Affymetrix GeneChip 3000 Scanner
according to the Affymetrix GeneChip WT Terminal
Labeling and Hybridization User Manual.
Statistical analysis
Signals from gene expression profiling were background
adjusted and quantile normalized. A permutation test and
a false discovery procedure [53] were used to identify most
deregulated genes between tumoral and normal samples.
Genes presenting a p-value <0.05 for both t-test and
permutation test were considered for further analyses.
Principal component analysis and unsupervised hierarchical
clustering were performed on deregulated features in order
to discover groups of samples with different histotype. All
signal processing analyses and statistical tests were
performed by Matlab (The MathWorks Inc.). Several
prediction target softwares were interrogated by using
the web server tool MirWalk2 (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2/) and the most pre-
dicted putative targets of a miRNA signature were selected
to evaluate miRNA\mRNA positive and negative correl-
ation. mRNAs predicted to be targeted by at least 2 predic-
tion algorithms were considered. A Spearman correlation
coefficient and relative p-value were obtained for each
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miRNA\mRNA pairs, and genes with p-values less than
0.05 were used for further analyses.
Pathway prediction
Gene annotation enrichment analysis of the identified
signatures of mRNAs deregulated in tumor vs normal
samples was performed using DAVID program (https://
david.ncifcrf.gov/) [54, 55].
cDNA synthesis and RT-qPCR
Reverse Transcription and RT-qPCR quantification of
miR-145-5p expression were performed respectively by
TaqMan MicroRNA RT assay (Applied Biosystems, Fos-
ter City, CA, USA) and TaqMan MiRNA® Assays (Ap-
plied Biosystems, Foster City, CA, USA) according to
the manufacturer's protocol. RNU6B and RNU49 were
used as endogenous controls to standardize miR-145-5p
expression in human samples. Whereas as endogenous
control to standardize miR-145-5p expression in TC1889
cells was used the RNU19. All reactions were performed
in duplicate. To validate data obtained by microarray RNA
from 2 normal and 6 tumor samples used in array experi-
ments was anlyzed by RT-qPCR for the expression of a
subgroup of genes (Golm-1, Psat-1, CDH2). Reverse Tran-
scription and qPCR were performed respectively by
MMLV RT assay (Thermo Fisher Scientific, Waltham,
MA USA) and Sybr green® assays (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer's
protocol. GAPDH and RPL19 were used as endogenous
controls to standardize gene expression. All reactions were
performed in duplicate. Total RNA from TC1889 cells
was extracted using the TRIZOL Reagents (Gibco®
Thermo Fisher Scientific, Waltham, MA USA) and 500 ng
of total RNA were reverse-transcribed at 37 °C for 60 min
using High-Capacity RNA-to-cDNA Kit (Applied Biosys-
tems, Foster City, CA, USA) and diluted 1:5 for the fol-
lowing PCR reactions. The list of primers used is
showed in Additional file 1: Table S6.
Immunohistochemistry
Golm-1 and CDH2 proteins expression were analyzed
by immunohistochemistry (IHC) in a set of 19 FFPE
thymic tumors and 10 normal counterparts from cases
previously described and showing miR-145-5p deregula-
tion [43]. 5 μm-thick sections were Haematoxylin and
Eosin stained. Serial/subsequent sections were stained
with the anti-Golm-1 antibody (#PA5-30622, Thermo
Fisher Scientific, Waltham, MA USA) and the anti-
CDH2 antibody (#ab18203, Abcam, Cambridge, UK) in
the Ventana Staining System (Benchmark Ultra Ventana,
Roche, Tucson, USA). Slide evaluation was independently
and blinded performed by MM and EG. Overall inter-
observer difference was 5%. In case of differing results,
consensus was reached by joint evaluation. The following
scoring approach in the assessment of Golm-1 and CDH2
immunostaining was used: score 0 = no staining or unspe-
cific staining of tumor cells; score >1 from moderate to
strong staining of more than 10% of tumor cells.
Cell culture, transfection and treatment
Human Thymic Carcinoma cell line TC1889 was cul-
tured in RPMI 1640 (Gibco® Thermo Fisher Scientific,
Waltham, MA USA) containing 4.5 g/L glucose, 25 mM
Hepes, 50 U/mL penicillin, 50 U/ml streptomycin and
10% heat-inactivated South-American Fetal Bovine Serum
(FBS) (Gibco® Thermo Fisher Scientific, Waltham, MA
USA) at 37 °C in incubator with humidified 5% CO2
atmosphere [40, 56].
Pre-miRNA-145 (#AM17100, Thermo Fisher Scientific,
Waltham, MA USA) and Pre-miRNA Precursor Negative
Control (#AM17110, Thermo Fisher Scientific, Waltham,
MA USA), were transiently transfected at final concentra-
tion of 5nM using Lipofectamine RNAiMAX (Gibco®
Thermo Fisher Scientific, Waltham, MA USA) according
to the manufacturer’s instructions. For gene silencing
experiments, TC1889 cells were transiently transfected
with 250 pmols of Dicer-substrate short interfering RNAs
(DsiRNAs) (IDT, Leuven, Belgium) for Golm-1, CDH2
and NC1 negative control for 72 h. For the inhibition of
miR-145-5p expression, TC1889 cells were transiently
transfected with hsa-miR-145-5p mirVana miRNA inhibi-
tor (#MH11480, Thermo Fisher Scientific, Waltham, MA
USA) and negative control #1 (#4464077, Thermo Fisher
Scientific, Waltham, MA USA) at final concentration of
5nM using Lipofectamine RNAiMAX (Gibco® Thermo
Fisher Scientific, Waltham, MA USA) according to the
manufacturer’s instructions. TC1889 cells transfected for
48 h with the inhibitor of miR-145-5p or negative control
were subsequently treated with 0.5 mM Valproic acid
sodium salt (VPA) (#P4543, Sigma-Aldrich, Darmstadt,
Germany) for additional 24 h. Treatment with VPA
(#P4543, Sigma-Aldrich, Darmstadt, Germany) as single
agent was performed at a concentration of 3 mM (or as
indicated) for the indicated time. For the combination
treatment TC1889 cells were treated for 8 h with VPA
(3 mM) and subsequently with or without Cisplatin
(CDDP, 7.5μg/mL) (Pfizer, New York, NY, USA), for
additional 48 h.
Erlotinib (#5083 Cell Signaling, Danvers, MA, USA)
was used in TC1889 cells as single agent in a dose-
dependent treatment (as indicated). In Fig. 6d Erlotinib
was used at 2.5 μM and 5 μM as single agent or in co-
treatment with VPA (3 mM) for 72 h.
Lysate preparation and immunoblotting analysis
Cells were lysed in 2% SDS buffer (25 mM Tris–HCl
pH 7.5, 100 mM Nacl, 3 mM EDTA, 7% Glycerol) and
fresh protease inhibitors. Extracts were sonicated for
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10 s and centrifuged at 12000 × rpm for 10 min to re-
move cell debris. Western blotting was performed using
the following primary antibodies: mouse monoclonal
anti-Gapdh 6C5 (#sc32233, Santa Cruz Biotechnology,
Heidelberg Germany); mouse monoclonal anti-b-Actin
(ACTBD11B7) (#sc-81178, Santa Cruz Biotechnology,
Heidelberg Germany); mouse monoclonal anti-Tubulin
B512 (#T5168, Sigma-Aldrich, Darmstadt, Germany); rabbit
polyclonal anti-Golm1 (#PA5-30622, Thermo Fisher
Scientific, Waltham, MA USA); rabbit monoclonal anti-
Synaptophysin (#ab32127, Abcam, Cambridge, UK); mouse
polyclonal anti-Psat1 (#PA5-22124, Thermo Fisher
Scientific, Waltham, MA USA), rabbit polyclonal anti-
CDH2 (#ab18203, Abcam, Cambridge, UK), rabbit
monoclonal anti-EGFR (#C74B9, Cell Signaling, Danvers,
MA, USA) and rabbit polyclonal anti-p21 (12D1) (#2947
Cell Signaling, Danvers, MA, USA). As secondary anti-
bodies goat anti-mouse and anti-rabbit conjugated to
horseradish peroxidase were used (Bethyl Laboratories,
Montgomery, TX, USA). Western blot analysis was per-
formed with the aid of the enhanced chemiluminescence
system (Thermo Fisher Scientific, Waltham, MA USA).
ECL detection was done using a ChemiDoc-It Imaging
System (UVP, Upland, CA) instrument.
Transwell migration assay
Migration assay was performed by using a 24-well plate
with a non-coated 8-mm pore size filter in the insert
chamber (BD Falcon, Franklin Lakes, NJ, USA). Cells
were transfected with pre-miRNA145 (for 120 h), or si-
lenced with siGolm-1 at 250 pmoli (for 72 h), or silenced
with siCHD2 at 250 pmoli (for 72 h) or treated with
3 mM VPA (for 72 h). After transfection or treatment,
5×104 cells were resuspended in TC1889 medium without
FBS and seeded into the insert chamber. Cells were
allowed to migrate for 24 h into the bottom chamber con-
taining 0,7 ml of TC1889 medium containing 30 ng/ml of
epithelial growth factor (EGF) (#E9644, Sigma-Aldrich,
Darmstadt, Germany) in a humidified incubator at 37 °C
in 5% CO2. Cell migration was measured by counting the
number of cells stained with DAPI on the underside of
the membrane.
Clonogenic assays
TC1889 cell lines were grown to 70% confluence and
treated with VPA 3 mM. After 72 h of treatment, cells
were detached and seeded at 1×103 cells/well into 6-well
dishes in drug-free media. Fresh media (25%) was added
every three days. Colonies were stained with crystal violet
and were counted after 10–14 days by ImageJ software.
Immunocytochemistry and morphological analysis
For immunocytochemistry assay cells were seeded onto
glass coverslips at 25×104 cells/well into 6-well dishes
and transfected with pre-miRNA-145 (#AM17100, Thermo
Fisher Scientific, Waltham, MA USA) and pre-miRNA
Precursor Negative Control (#AM17110, Thermo Fisher
Scientific, Waltham, MA USA), at final concentration
of 5nM for 96 h or treated with VPA for 72 h. Cells
were then fixed with 4% formaldehyde in PBS for 15 min
at room temperature (RT). Cells were permeabilized with
1% Triton X-100 in PBS for 10 min. After washing with
PBS, the coverslips were incubated with the indicated
antibody diluted in 5% BSA/PBS for 1 h at RT. Cells were
incubated with peroxidase inhibitor before primary anti-
body incubation. Protein staining was revealed through
DAB enzymatic reaction while nuclei were counterstained
with hematoxylin. Morphological analysis was performed
by the Wright-Giemsa-staining according to the manufac-
turer’s instructions.
Cell cycle analysis
For cell cycle analysis, 2×105 cells were resuspended in
50% FCS, fixed in 70% ethanol for 24 h, incubated with
50 μg/ml propidium iodide (Sigma-Aldrich, Darmstadt,
Germany) and 50 units/ml Dnase-free RNase A (Sigma-
Aldrich, Darmstadt, Germany) and analyzed after 3 h
(1×104 events) using an Epics XL Cytometer (Beckman
Coulter, Brea, CA, USA).
ATPlite Luminescence Assay System
ATPlite™ Luminescence Assay was performed by using a
96-well plate with 2×104 cells/well and cell viability was
evaluated following the manufacturer’s instructions.
Luminescence was read by the EnSpire® Multimode
Plate Reader (PerkinElmer, Whaltman, MA, USA).
Formaldehyde cross-linking and chromatin
immunoprecipitation
Formaldehyde cross-linking and chromatin immunoprecip-
itation were performed as described [57]. The chromatin
solution was immunoprecipitated with an anti-acetyl-
Histone H4 antibody (#06-866 Millipore, Billerica, MA,
USA) or no antibody as negative control. Cyclin B1 first
intron was amplified as negative control. Primers for
the qPCR amplification of different miR-145-5p up-
stream genomic regions and negative control are re-
ported in Additional file 1: Table S6.
Plasmid construction and dual-luciferase reporter assay
The luciferase reporter assay was performed by using vec-
tors kindly provided us by Dr Naohiko Seki for Golm-1
[50] and Dr Peng Gao for CDH2 [48]. Briefly as described,
for Golm-1 the partial wild-type sequences of the Golm-1
3’-UTR or the mutant derivative lacking the miR-145-5p
target sites (positions 260–267 of the Golm-1 3’-UTR)
were inserted between the XhoI–PmeI restriction sites
in the 3’UTR of the hRluc gene in the psiCHECK-2
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vector (C8021; Promega, Madison, WI, USA) [50];
while for CDH2 the 3’-UTR sequence of CDH2 carry-
ing a putative miR-145-5p binding site was amplified by
PCR and cloned into a Taq-amplified (TA) vector
(pTA2, Takara, Ostu, Shiga, Japan) and then subcloned
into a pmirGLO miRNA target expression vector (Pro-
mega, San Lius Obispo, CA, USA) [48]. The TC1889 cells
were transfected for 48 h with 50 ng of the vectors and pre-
miRNA-145 (#AM17100, Thermo Fisher Scientific, Wal-
tham, MA USA) or pre-miRNA Precursor Negative Con-
trol (#AM17110, Thermo Fisher Scientific, Waltham, MA
USA) as indicated, using Lipofectamine RNAiMAX
(Gibco® Thermo Fisher Scientific, Waltham, MA USA)
according to the manufacturer’s instructions. The activ-
ities of firefly and renilla luciferases in cell lysates were de-
termined with a dual-luciferase assay system (E1910;
Promega, Madison, WI, USA). Normalized data for
Golm-1 and CDH2 were calculated, respectively, as the
ratio of renilla/firefly and firefly/renilla luciferase activ-
ities. The experiments were performed in duplicates.
Results
Differential mRNA expression between thymic epithelial
tumors and normal thymic tissues
Starting from a selection of frozen tissue samples showing
high RNA quality, we performed a gene expression profil-
ing using 6 TET specimens and 3 normal counterparts
(Fig. 1a). We identified 2328 genes differently expressed
between tumoral (T) and normal (N) samples. Among
these genes 1095 were up-regulated and 1233 were down-
regulated in thymic tumors (Fig. 1b and c and Additional
file 2: Table S1). By unsupervised hierarchical clustering
and Principal component analysis (PCA) we assessed that
they were able to clearly separate tumor tissues from
normal samples (Fig. 1c and Additional file 3: Figure S1A).
Functional analysis of these genes evidenced that many of
them converge on common pathways. In particular we
identified Cell adhesion molecules pathway, B cell recep-
tors signaling pathways, and additional pathways related
to cancer phenotype such as MAPK and Jak-Stat signaling
pathways (Fig. 1d and Additional file 4: Table S2).
We next searched whether putative targets of the miR-
NAs previously identified as commonly deregulated in all
TET histotype groups in our previous work were present
in the list of deregulated mRNAs [43]. Specifically, we
considered the 9 miRNAs most strongly deregulated in
TET (5 up-regulated: hsa-miR-34c-5p, hsa-miR-141-3p,
hsa-miR-205-3p, hsa-miR-455-5p, hsa-miR-132-3p, and 4
down-regulated: hsa-miR-486-5p, hsa-miR-630, hsa-miR-
451a, hsa-miR-145-5p). By using prediction algorithms on
the list of genes deregulated between tumor and normal
samples we identified a number of mRNAs, which are
putatively targeted by at least one of the nine deregu-
lated miRNAs. Evaluation of the Spearman correlation
coefficient between the mRNA/miRNA pairs led to the
identification of 1430 putative targets genes with ex-
pression pattern significantly correlated to the miR-
NAs (Fig. 1b and e and Additional file 3: Figure S1B);
among these genes, 682 were up-regulated and 748
down-regulated in thymic tumors (Fig. 1b and e and
Additional file 5: Table S3). Functional classification
analysis identified for these genes similar pathways as
those described above, except for Chemokine and
Cytokine-cytokine receptors signaling pathways (Fig. 1f
and Additional file 6: Table S4).
Identification of miR-145-5p inversely correlated target
mRNAs in TET tumors
Among the best 9 miRNAs deregulated in all histotype
groups of thymic tumors we previously evidenced the
down-regulation of miR-145-5p [43]. miR-145-5p down-
regulation is emerging as a common feature in various
malignancies [46–50]. Down-regulation of miR-145-5p
expression has been also confirmed in this selection of
frozen tissue samples (Fig. 2a). Analysis of miR-145-5p
putative targets evidenced a 69-gene signature of miR-
145-5p putative target mRNAs whose expression is
inversely correlated to that of miR-145-5p (Spearman
correlation coefficient and relative p-value < 0.05) (Fig. 2b
and Additional file 7: Table S5). Principal component
analysis (PCA) and unsupervised hierarchical clustering
of these 69 miR-145-5p putative targets show that these
genes not only separate tumor from normal tissues but
also, interestingly, clearly distinguish clinically relevant
histotype groups (A/AB from B2/B3) (Additional file 3:
Figure S1C). Validation of selected mRNAs was per-
formed on the same patients cohort by RT-qPCR and,
according to the expression profiling results, we evi-
denced the up-regulation of Golm-1, Psat-1 and CDH2
in tumor tissues compared to normal samples (Fig. 2c).
The protein up-regulation of Golm-1 and CDH2 was
also assessed by immunohistochemistry (IHC) using a
series of formalin-fixed paraffin embedded (FFPE) tissues
from 19 TET of different histotype (one Type A, five
Type AB, three Type B1, three Type B2, two Type B3
and five Thymic Carcinoma) and ten normal counterparts
included in our previous work [43]. As summarized in the
Fig. 2d-f and representatively reported in the Fig. 2 g the
IHC showed that both Golm-1 and CDH2 proteins are
expressed at higher levels (arbitrary score >1) in tumors
than in normal samples. Interestingly, 68% of tumor tis-
sues showed co-expression of Golm-1 and CDH2 (Fig. 2f).
Golm-1 and CDH2 proteins resulted not expressed or
expressed at low levels (arbitrary score =0) in all the
normal tissues analyzed (Fig. 2d, e and g).
By using luciferase reporter assay we validated that
CDH2 and Golm-1 are miR-145-5p target genes also in
the Thymic Carcinoma cell lines TC1889, as already
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published, respectively, for gastric [48] and prostate
cancer [50]. The vector containing wild-type fragment
of the 3’-UTR of Golm-1 mRNA or the mutant deriva-
tive lacking the putative miR-145-5p recognition se-
quence (position 260–267 of the Golm-1 3’UTR) [50]
was transfected together with miR-145-5p or negative
control in TC1889 cells. Luciferase expression of the
wild-type construct was significantly reduced when
miR-145-5p was expressed with respect to the negative
control (Additional file 8: Figure S2A). Repression was
abolished when the mutant miR-145-5p derivative was
utilized (Additional file 8: Figure S2A). Similarly, the
vector containing the sequence of the 3’-UTR of
CDH2 mRNA carrying a putative miR-145-5p binding
site [48] was transfected together with miR-145-5p or
negative control in TC1889 cells. Luciferase expression
was significantly reduced when miR-145-5p was expressed
with respect to the negative control (Additional file 8:
Figure S2B). Repression was not observed when the
empty vector was utilized (Additional file 8: Figure S2B).
Tissue Samples
# Tissue Histotype
1 Normal
2 Normal
3 Normal
4 Thymoma A
5 Thymoma AB
6 Thymoma AB
7 Thymoma B2
8 Thymoma B2
9 Thymoma B3
mRNAs mRNA putative targets  
 of  9 miRNAs
Up T vs N 1095 682
Down T vs N 1233 748
Total 2328 1430
B cell receptor 
signaling pathway 
Cell adhesion 
molecules (CAMs) 
Chemokine 
signaling pathway 
Cytokine-cytokine 
receptor interaction 
Adipocytokine 
signaling pathway 
MAPK signaling 
pathway 
Jak-STAT signaling 
pathway 
Cell adhesion 
molecules (CAMs) 
B cell receptor 
signaling pathway 
MAPK signaling 
pathway 
Adipocytokine 
signaling pathway 
Jak-STAT 
signaling pathway 
A 
B 
C D 
E F 
Fig. 1 Gene expression profiling of Thymoma versus normal Thymus tissues. a Table representing the normal and tumor samples used in the
experiment from two different cohorts and analyzed for gene expression profile. b Table showing the number of genes up and down-regulated
in tumor versus normal tissues. c Unsupervised clustering analysis representing the 2328 genes differentially expressed between tumor and normal
thymus tissues (p-value < 0.05, see material and methods). d Pie chart representing pathway enrichment analysis of the deregulated genes by David
tools (p-value < 0.05). e Unsupervised clustering analysis representing the putative targets of the best 9 of 22 miRNAs common to histotype groups of
thymic tumors compared to normal tissue (see material and methods and Ganci et al., [43]) f) Pie chart representing pathway enrichment analysis of
the deregulated genes by David tools (p-value < 0.05)
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These data suggested that miR-145-5p bound directly
to specific sites in the 3’UTR of Golm-1 and CDH2
mRNAs.
We next evaluated the expression levels of miR-145-5p
putative target mRNAs after overexpression of miR-145-5p
in TC1889 cell line. As expected, we observed that the
miR-145-5p overexpression resulted in the down-regulation
of Golm-1 and Psat-1 (negatively correlated to the
expression of miR-145-5p in the microarray analysis of
TET samples) and in the up-regulation of Pcdh9 and
Cldn1 (positively correlated to the expression of miR-
145-5p in the microarray analysis of TET samples)
(Fig. 3a and Additional file 8: Figure S2C). Accordingly,
miR-145-5p overexpression resulted in the protein level
down-regulation of Golm-1 and Psat-1, as assessed by
Western-blot and immunocytochemistry (Fig. 3b and c).
Fig. 2 Expression profiling of putative targets of miR-145-5p in Thymoma versus normal Thymus tissues. a Box plot showing the modulation of
miR-145-5p expression in the group of 6 tumors and 3 normal samples used to evaluate gene expression profiling. b Unsupervised clustering analysis
representing the expression of putative targets of miR-145-5p inversely correlated to miR-145-5p expression in thymic tumors compared to normal
tissues. c Validation by RT-qPCR of mRNA expression of three putative targets of miR-145-5p, Golm-1, Psat-1 and CDH2, in the same dataset of samples
used for gene expression profiling (2 normal tissues and 6 tumors). d-e Table showing the number of Golm-1 and CDH2 positive (score > 1)
and negative (score 0) samples in the subset of normal and tumor tissues of each histotype. f Table showing the number of Golm-1 and CDH2 co-
expressing samples in the subset of tumor tissues of each histotype. g Expression of Golm-1 and CDH2 protein by immunohistochemistry (IHC) analysis in
a representative normal thymus and tumor tissues of each histotype
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Interestingly, the overexpression of miR-145-5p, as well as
the silencing of its targets Golm-1 (siGolm-1) and CDH2
(siCDH2) by siRNA, also led to reduced tumorigenic
features of these cells, as evidenced by their reduced
migration capability (Fig. 3d and e and Additional file 8:
Figure S2D), supporting their contribution to TET pheno-
type. In addition, miR-145-5p overexpression led to mor-
phological changes with increased cell-cell contacts and
appearance of cells with a neuroepithelial-like features
whose existence has been previously reported in Thymic
cultures [58] (Fig. 3c). This agrees with the increased
levels of the synaptophysin protein, a neuroendocrine
differentiation marker, observed after miR-145-5p overex-
pression (Fig. 3b).
Inhibition of HDAC activity releases miR-145-5p expression
and reduces tumor phenotype of TET cells
To verify whether miR-145-5p expression is regulated at
epigenetic level in Thymic Carcinoma (TC1889) cells,
we evaluated the effect of an HDAC inhibitor (Valproic
Acid, VPA) on miR-145-5p expression. As shown in Fig. 4a,
miR-145-5p is significantly up-regulated following VPA
treatment (72 h). According to this result, we evidenced, by
Chromatin Immunoprecipitation (ChIP) analysis, an in-
creased histone H4 acetylation (H4Ac) level following
3 mM VPA treatment (24 h) on miR-145 upstream gen-
omic regions R1 and R2 (R1 located at -1500 bp and R2
located at -1000 bp) (Fig. 4b). This increase was not
present on a negative control genomic region (intronic
region of CCNB1 gene, indicated as Int B1). Interest-
ingly, we observed that, although the VPA treatment
significantly up-regulates the mRNA expression levels
of Golm-1, Psat-1 and CDH2 (Fig. 4c), the protein
expression of these miR-145-5p targets was down-
regulated after VPA treatment, as assessed by WB and
immunocytochemistry, suggesting that miR-145-5p inhibi-
tory activity on translation of these targets is maintained
and prevalent (Fig. 4d and e). Moreover, we evidenced that
VPA treatment increases the expression levels of the
synaptophysin protein and induces morphological changes
as previously described in the miR-145-5p overexpressing
cells (Fig. 4d and e and Fig. 3b-c). To further characterize
the impact of VPA on TET phenotype of TC1889 cells, we
evaluated its effect on cell cycle distribution. We observed
that VPA treatment induced G1 arrest after 72 h, cell
death after 96 h (Fig. 5a) and a dose-dependent induction
Fig. 3 Overexpression of miR-145-5p in a Thymic Carcinoma (TC1889) cell line. a RT-qPCR to evaluate the expression levels of miR-145-5p
inversely correlated (Golm-1 and Psat-1) and positively correlated (Pcdh9 and Cldn1) genes after miR-145-5p overexpression in TC1889 cells.
b Western-blot analysis of Golm-1 and Synaptophysin (SYP) proteins after 72 h and 96 h of miR-145-5p overexpression in TC1889 cells. c Morphological
and IHC analyses for Golm-1 and Psat-1 of miR-145-5p overexpression in TC1889 cells after 144 h or 96 h respectively. d-e Evaluation of the impact of
miR-145-5p overexpression or siRNA for Golm-1 (siGolm-1) in TC1889 by migration assay after 120 h and 72 h respectively. P-value was calculated by
unpaired t-test and a value of P ≤ 0.05(*), P ≤ 0.01(**) and P ≤ 0.0001(****) was considered statistically significant
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of cell cycle master regulator p21 after 72 h of treatment
(Fig. 5b). In addition, VPA treatment (24 h) inhibited cell
viability in a dose dependent manner (Fig. 5c). Finally, as
shown in Fig. 5d and e, we evidenced that VPA treatment
(72 h) inhibited the colony forming ability and migration
capability of TC1889 cells. Of note, to support that the
impact of VPA on TET phenotype was, at least in part,
mediated by the induction of miR-145-5p, we evaluated
the cell viability and the colony forming capability of
VPA-treated TC1889 cells after the inhibition of miR-145-
5p expression. We observed that the treatment of TC1889
cells with the miR-145-5p inhibitor (INH-145) signifi-
cantly impaired the VPA-dependent reduction of cell
viability and colony forming capability compared to the
same cells treated with a scramble inhibitor (INH-C)
(Fig. 5f and g, Additional file 8: Figure S2E).
Inhibition of HDAC activity sensitizes TET cells to
chemotherapy and to EGFR tyrosine kinase inhibitor
To evaluate whether VPA treatment modulates the sen-
sitivity of TET cells to chemotherapeutic treatment, we
pretreated Thymic Carcinoma cells for 8 h with VPA
(3 mM) and subsequently we added or not Cisplatin
(CDDP, 7.5μg/mL) for additional 48 h. FACS analysis
evidenced that VPA treatment sensitizes TET cells to
CDDP-dependent cell death (Fig. 6a and b).
Fig. 4 Inhibition of HDAC activity releases miR-145-5p expression resulting in miR-145-5p target genes modulation. a RT-qPCR to evaluate the
expression levels of miR-145-5p after 72 h of 3 mM VPA treatment of TC1889 cells. b Schematic representation miR-145-5p upstream genomic
region (upper panel) and Chromatin Immunoprecipitation (ChIP) analysis (lower panel) to evaluate the histone H4 acetylation (H4Ac) status of R1
and R2 miR-145 upstream genomic regions (R1 located at -1500 bp and R2 located at -1000pb) after 24 h of 3 mM VPA treatment in TC1886 cells.
The intronic region of CCNB1 gene (Int B1) was used as negative control. c RT-qPCR to evaluate the expression levels of Golm-1, EGFR, CDH2 and
Psat-1 after 72 h of 3 mM VPA treatment of TC1889 cells. d Wester blot analysis to evaluate Golm-1, EGFR and SYP after 24 h and 48 h of 3 mM
VPA treatment of TC1889 cells. e Morphological and IHC analyses for Golm-1, EGFR, CDH2 and Psat-1 after 72 h of 3 mM VPA treatment of TC1889 cells.
P-value was calculated by unpaired t-test and a value of P ≤ 0.05(*), P ≤ 0.01(**) and P ≤ 0.001(***) was considered statistically significant
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We next evaluated the effect of combined therapy of
VPA plus Erlotinib, an EGFR tyrosine kinase inhibitor,
being Erlotinib under investigation as potential thera-
peutic agent in TET, especially in patients with heavily
pretreated thymoma. EGFR protein is indeed highly
expressed in TET and also in TC1889 cells (as previously
shown in Fig. 4d), where its level is decreased following
VPA treatment.
As shown in Fig. 6c, dose-dependent treatment with
Erlotinib for 72 h significantly affects the viability of
TC1889 cells. To evaluate whether VPA treatment modu-
lates the sensitivity of TET cells to Erlotinib we co-treated
TET cells with VPA (3 mM) and Erlotinib at 2.5 μM and
5 μM. As shown in Fig. 6d viability of TC1889 cells is
significantly reduced after treatment with VPA + Erlotinib
compared to single treatments.
Discussion
Epigenetic therapy is recognized as an effective and well-
tolerated treatment of cancer [59]. In particular, histone
Fig. 5 Inhibition of HDAC activity reduces tumor characteristics of TET cells. a Representative cell cycle analysis of TC1889 cells after 72 h and
96 h of 3 mM VPA treatment. b Western-blot analysis to evaluate the expression levels of p21 after 72 h of 1 mM or 3 mM VPA treatment. c
ATPlite analysis to evaluate the viability of TC1889 cell after 24 h of a dose-dependent VPA treatment. d Evaluation of the impact of 3 mM VPA
treatment for 72 h on TC1889 colony forming capability. The experiment was performed in triplicate and the graphical plot of the average (left
panel) and a representative image (right panel) were reported. e Evaluation of the impact of 3 mM VPA treatment for 72 h on TC1889 migration
capability. The experiment was performed in triplicate. f-g ATPlite analysis f and colony forming capability (g) of TC1889 cells treated for 48 h with
the inhibitor of miR-145-5p (INH 145) or negative control (INH C) and subsequently treated with VPA 0.5 mM for additional 24 h. The experiment
was performed in triplicate. P-value was calculated by unpaired t-test and a value of P ≤ 0.01(**), P ≤ 0.001(***) and P ≤ 0.0001(****) was considered
statistically significant
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deacetylases (HDACs) are considered to be among the
most promising targets in drug development for cancer
therapy [60, 61].
To translate in TET management the therapeutic ex-
perience on epigenetic drugs already acquired in other
tumors [59, 62], we explored here the possibility that
Valproic Acid (VPA), an HDAC inhibitor, might synergize
with other drugs to impair the epigenetic mechanisms at
the basis of TET phenotype. To date chemotherapy or
targeted therapy represent the frontline for the medical
treatment of TETs although the rarity of this tumor type
has precluded it from large phase II and III clinical trial
investigations, and new drug development for TET treat-
ment has progressed slowly [12].
Systemic chemotherapy is used for induction therapy,
in cases of stage III/IVA, and currently represents the
standard therapy for metastatic or inoperable refractory/
recurrent disease [10]. Cisplatin-based combined chemo-
therapy currently represents the standard therapy for
TETs with an important contribution of anthracyclines
[12]. Cisplatin-based regimens, such as the PAC scheme
(cisplatin, adriamycin, and cyclophosphamide) are most
frequently used [63] and recently the use of belinostat, a
histone deacetylase (HDAC) inhibitor, administered
before and in combination with PAC, indicated that the
combination is active in TETs [25].
Also targeted therapy has recently emerged in TET
management and the use of EGFR-tyrosine kinase
inhibitors (TKI) (Erlotinib or Gefitinib) or anti-EGFR
mAb (Cetuximab) are currently under investigation as
potential therapeutic agents in TET, especially in pa-
tients with heavily pretreated thymoma [12, 23, 64–66].
Interestingly, a recent work highlighted that the histone
deacetylase (HDAC) inhibitor Valproic Acid (VPA)
might markedly increase the sensitivity of TKI-resistant
lung adenocarcinoma cells to Erlotinib [24].
We here demonstrate that the inhibition of HDAC
activity by VPA sensitizes TET cells to Cisplatin (CDDP) or
to EGFR tyrosine kinase inhibitor, supporting the possibility
of a combination approach to improve the therapeutic
response of TET malignancies. Of note, the treatment
of VPA as single agent is able itself to impact on TET
phenotype as evidenced by the induction of cell cycle
arrest and reduction of cell viability, colony forming
ability and migration capability in TET cells. These results
support the involvement of epigenetic mechanisms in
Fig. 6 Inhibition of HDAC activity sensitizes TET cells to chemotherapy. a-b FACS analysis to evaluate the percentage of TC1889 Propidium Iodate
(PI) positive cells treated with Cisplatin (CDDP, 7.5μg/mL) for 48 h and pretreated or not with 3 mM of VPA for 8 h as indicated. The experiment
was performed in triplicate and the graphical plot of the average (a) and a representative FACS analysis (b) were reported. c ATPlite analysis to
evaluate the viability of TC1889 cells after 72 h of a dose-dependent treatment with Erlotinib. d ATPlite analysis in TC1889 cells co-treated with
Erlotinib (2.5μM or 5μM) and 3 mM of VPA for 72 h. The experiment was performed in triplicate. P-value was calculated by unpaired t-test and a
value of P ≤ 0.05(*), P ≤ 0.01(**), P ≤ 0.001(***) and P ≤ 0.0001(****) was considered statistically significant
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TETs. Specifically, VPA treatment is able to induce
chromatin-remodeling events on the upstream regula-
tory regions of miR-145-5p, resulting in the induction
of miR-145-5p expression and supporting its epigenetic
de-regulation in TET cells. Following VPA treatment,
miR-145-5p shows not only increased expression levels,
but also the ability to exert its activities in TC cells.
Indeed, while following VPA treatment we observe in-
creased mRNA level of miR-145-5p target genes Golm-
1, CDH2 and Psat-1, which is probably the effect of a
general increase in transcription rate due to HDAC in-
hibition, protein analysis of these target genes revealed
a clear decrease in their expression level, indicating
the activation of a strong post-transcriptional control
program on these mRNAs. These results suggest that
the mechanisms controlling the translation of these
mRNA are predominant on the transcriptional ones
during VPA treatment.
Contrarily to Golm-1, CDH2 and Psat-1, no changes
in EGFR mRNA level following VPA treatment were
observed, while protein analysis of this miR-145-5p tar-
get gene revealed a clear decrease in its expression
level, indicating the activation of a strong post-
transcriptional control program on this mRNA. These
results suggest that also for this miR-145-5p target gene
the mechanisms controlling its translation are predom-
inant on the transcriptional ones during VPA treatment
in TET cells. Moreover, it was recently reported the in-
volvement of miR-145-5p in the negative regulation of
EGFR expressions at both mRNA and protein levels
[67]. Thus, we cannot exclude the involvement of miR-
145-5p in the transcriptional control of EGFR regula-
tion also in TET cells.
The increased miR-145-5p activity also contributes,
even if not the solely responsible, to the functional
impact of VPA on TET phenotype, evaluated as cell via-
bility and colony forming capability. In this context, the
identification of a signature of genes positively and nega-
tively associated to miR-145-5p expression could
strongly contribute to the deciphering of the molecular
mechanisms governed by or governing miR-145-5p ex-
pression. In this direction we have identified a 69-gene
signature of miR-145-5p putative target mRNAs whose
expression is inversely correlated to that of miR-145-5p
and that could participate to the maintenance of TET
phenotype. Moreover, starting from the analysis of
mRNAs differently expressed between tumoral (T) and
normal (N) samples we identified several genes deregu-
lated in TET and belonging to different signaling path-
ways related, for example, to cell adhesion and motility
pathways or to cancer phenotype such as MAPK and
Jak-Stat signaling pathways. Interestingly, the pathways
that resulted significantly enriched in tumor vs normal
tissues include signaling networks related to immune-
related functions (as for example B cell receptor signal-
ing, Chemokine signaling, Cytokine-cytokine receptor
pathways). In particular we noticed that the majority of
genes belonging to B cell receptor signaling (16 out of
19), to Chemokine signaling (23 out of 29) or to
Cytokine-cytokine receptor pathways (33 out of 37) were
down-regulated in tumoral vs normal tissues indicating
a loss of the immune-related functions in TET.
A deeper characterization of deregulated genes and
miRNAs in TET could lead to the identification of rele-
vant players involved in the physiopathological function
of thymic epithelial tissue.
Conclusion
In summary these results suggest that the epigenetic
regulation of the miR-145-5p expression, as well as the
modulation of its functional targets, could be a relevant
player in tumor progression and treatment response in
TET. Further study in a larger thymic tumor series will
allow the identification of miR-145-5p target genes spe-
cifically associated to each subtype and the relevance of
the identified genes for malignancy progression and
treatment response in TET.
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